BCL11B: A Potential Drug Target for Cellular Processes (G64919)

Target Name: BCL11B

NCBI ID: G64919

BCL11B

BCL11B: A Potential Drug Target for Cellular Processes

BCL11B (ATL1-alpha), a protein that belongs to the BCL1 family, plays a crucial role in the regulation of cell growth, apoptosis, and other cellular processes. It is a highly conserved transmembrane protein that is expressed in various tissues and cells throughout the body.

In recent years, BCL11B has gained significant attention as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in cell survival and proliferation makes it an attractive target for small molecules, antibodies, or other therapeutic agents that can inhibit its activity.

BCL11B is a key regulator of the cell cycle, and its activity is required for the proper progression of the cell from G1 to S and G2 phases. During the S phase, BCL11B is involved in the regulation of the nuclear envelope, which is responsible for controlling the movement of proteins into the cell nucleus. BCL11B plays a vital role in the formation of the nuclear envelope by interacting with various nuclear proteins, including Nup protein and TBP, which are known to be components of the nuclear export machinery.

In addition to its role in cell cycle regulation, BCL11B is also involved in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. During apoptosis, BCL11B plays a key role in the formation of the apoptotic vacuole, which is the final barrier that separates the cell from the surrounding environment.

BCL11B is also involved in several signaling pathways that regulate cell growth and differentiation. One of the well-known signaling pathways that BCL11B is involved in is the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell survival, proliferation, and angiogenesis. BCL11B is known to interact with the protein kinase Akt, which is a key component of the PI3K/Akt signaling pathway. This interaction between BCL11B and Akt suggests that BCL11B may be a potential drug target for therapies that target this pathway.

Another signaling pathway that BCL11B is involved in is the TGF-β signaling pathway. This pathway is involved in the regulation of cell growth, differentiation, and angiogenesis. BCL11B has been shown to interact with the transcription factorSMAD1, which is a key component of the TGF-β signaling pathway. This interaction between BCL11B and SMAD1 suggests that BCL11B may be a potential drug target for therapies that target this pathway.

In conclusion, BCL11B is a protein that plays a crucial role in the regulation of cell growth, apoptosis, and other cellular processes. Its involvement in several signaling pathways makes it an attractive target for small molecules, antibodies, or other therapeutic agents that can inhibit its activity. Further research is needed to fully understand the role of BCL11B in disease and to develop effective therapies that target its activity.

Protein Name: BCL11 Transcription Factor B

Functions: Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of hematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus (PubMed:27959755). Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4(+) T-lymphocytes (PubMed:16809611). Tumor-suppressor that represses transcription through direct, TFCOUP2-independent binding to a GC-rich response element (By similarity). May also function in the P53-signaling pathway (By similarity)

The "BCL11B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCL11B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets